Tobam Buys 19,208 Shares of Moderna, Inc. (NASDAQ:MRNA)

Tobam raised its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 75.2% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 44,753 shares of the company's stock after acquiring an additional 19,208 shares during the period. Tobam's holdings in Moderna were worth $1,269,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Sentry Investment Management LLC acquired a new position in shares of Moderna during the 1st quarter worth approximately $31,000. Wilmington Savings Fund Society FSB increased its holdings in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after buying an additional 587 shares during the last quarter. Compass Planning Associates Inc acquired a new position in Moderna during the fourth quarter worth $37,000. Venturi Wealth Management LLC raised its position in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after acquiring an additional 664 shares in the last quarter. Finally, Crowley Wealth Management Inc. acquired a new stake in Moderna in the fourth quarter valued at $41,000. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Stock Down 2.5%

Shares of NASDAQ:MRNA traded down $0.68 during trading on Friday, reaching $26.67. 7,146,605 shares of the company traded hands, compared to its average volume of 8,388,624. The firm has a market capitalization of $10.31 billion, a PE ratio of -2.87 and a beta of 1.86. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $145.74. The company's 50 day moving average is $26.25 and its two-hundred day moving average is $33.16.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. The firm had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business's revenue for the quarter was down 35.3% on a year-over-year basis. During the same period in the prior year, the company posted ($3.07) earnings per share. As a group, research analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

Wall Street Analyst Weigh In

MRNA has been the topic of several recent analyst reports. Barclays lowered their price objective on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Friday, May 2nd. Morgan Stanley dropped their price objective on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. UBS Group cut their price objective on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Royal Bank of Canada decreased their target price on Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Finally, Evercore ISI cut their price target on Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a report on Friday, May 2nd. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $46.61.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.